Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | Director | February 22, 2024 | February 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date February 22, 2024 · Filed February 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2034-02-21 | Direct | 30,000 |
Reported balance
After 2024-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-22 · Grant · Acquired 30,000 · Balance 30,000 F1: The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2024 Filed Feb 26, 2024 18:01 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001209191-24-003968 · doc4.xml · derivative · entry 1 Poole Robert Michael · CIK 0001871782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-02-21 F1 · derivative.exercise_date: The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 17:01 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-23-013251 · doc4.xml · derivative · entry 1 Poole Robert Michael · CIK 0001871782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-02-22 F1 · derivative.exercise_date: The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 20:51 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-22-007329 · doc4.xml · derivative · entry 1 Poole Robert Michael · CIK 0001871782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The option will vest in full on February 3, 2023 subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 09, 2021 Filed Jul 13, 2021 16:25 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001209191-21-046497 · doc4.xml · derivative · entry 1 Poole Robert Michael · CIK 0001871782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-07-08 F1 · derivative.exercise_date: The option shall vest as follows: 1/36th of the shares subject to the option shall vest every month after July 9, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2017 Equity Incentive Plan) on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.